Podcast - Quality by Design: Where We Stand Now - - BioPharm International

ADVERTISEMENT

Podcast - Quality by Design: Where We Stand Now





Add this Podcast feed to your media player



Quality by Design: Where We Stand Now

On what aspects of Quality by Design is there now consensus within the industry and regulatory bodies, and what remains to be sorted out?

Join Laura Bush, Editor in Chief of BioPharm International and John Towns, Senior Director of Global CMC Regulatory Affairs at Eli Lilly, as they discuss the current state of QbD.



Click here to go to the main podcast page >>>

Related Links:
Quality by Design for Biotechnology Products—Part 1: A PhRMA Working Group's advice on applying QbD to biotech.

Convincing the Skeptics

Quality by Design A-MAb Case Study Challenges Conventional Thinking
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here